XM does not provide services to residents of the United States of America.
S
S

Sanofi

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Soros Fund Management LLC Cuts Share Stake In Amazon, Raises In Astrazeneca Plc, American International Group

BRIEF-Soros Fund Management LLC Cuts Share Stake In Amazon, Raises In Astrazeneca Plc, American International Group Aug 14 (Reuters) - Soros Fund Management LLC SOROS FUND MANAGEMENT LLC CUTS SHARE STAKE IN AMAZON COM INC BY 26.5% TO 290,854 SHARES - SEC FILING SOROS FUND MANAGEMENT LLC RAISES SHARE STAKE IN ASTRAZENECA PLC BY 512.9% TO 2.5 MILLION
A
A
M
S

FDA approves Incyte's treatment for chronic graft-versus-host disease

UPDATE 2-FDA approves Incyte's treatment for chronic graft-versus-host disease Rewrites throughout, adds analyst comment in paragraph 9 By Christy Santhosh and Sruthi Narasimha Chari Aug 14 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Incyte's INCY.O treatment for chronic graft-versus-host disease (GvHD), a potentially fatal complication that could occur after a stem cell transplant.
I
S

MeiraGTx Announces Pricing Of Offering Of Ordinary Shares Led By Sanofi

BRIEF-MeiraGTx Announces Pricing Of Offering Of Ordinary Shares Led By Sanofi Aug 12 (Reuters) - MeiraGTx Holdings PLC MGTX.O : MEIRAGTX ANNOUNCES PRICING OF OFFERING OF ORDINARY SHARES LED BY SANOFI MEIRAGTX HOLDINGS: GROSS PROCEEDS FROM OFFERING EXPECTED TO BE $50 MILLION MEIRAGTX HOLDINGS: PRICING OF UNDERWRITTEN OFFERING OF 12.5 MILLION OF ORDI
S

IDT Australia rises after contract win

BUZZ-IDT Australia rises after contract win ** Shares of IDT Australia IDT.AX rise as much as 8.7% to A$0.125 ** Shares on track for their best day since July 12, if gains hold ** The pharma manufacturer secures contract with Sanofi Australia for pre-clinical formulation, development and manufacture of Sanofi's messenger RNA technology for its tran
S

German panel endorses GSK, Pfizer RSV vaccines for elderly

German panel endorses GSK, Pfizer RSV vaccines for elderly FRANKFURT, Aug 8 (Reuters) - Germany's influential vaccine advisory panel said on Thursday that everyone in the country who is 75-years old or more should receive one of two new vaccines against the common respiratory infection RSV. The panel of independent experts known as STIKO said in a statement that one shot, either Pfizer's PFE.N Abrysvo or Arexvy by GSK GSK.L , should be administered ideally in September or October before the cold
A
G
P
S

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.